Overview

A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Deltanoid Pharmaceuticals
Treatments:
Calcitriol
Vitamin D